An observational study in Severe Eosinophilic Asthma, sponsored by AstraZeneca. Recruiting at 36 sites in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by AstraZeneca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.
Among the 359 studies in Asthma by AstraZeneca, this one is the 47th largest by planned enrollment of the 110 observational ones that give a count, is one of 13 that started in 2025, is one of 111 observational ones, reaches primary completion later than 16 of the 27 other live ones, and was the 339th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in China
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
AstraZeneca · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Argentina, Czechia and 4 more countries
Ages 4–11
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
359 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 52 · Phase 3 123 · Phase 4 23
First in 1996; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 175 across the 248 interventional studies, 500 across the 110 observational. Of the 330 that completed or were terminated, 129 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
13 of the studies in Asthma by AstraZeneca that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
| NCT07218172AstraZenecaCharacterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 359 studies in Asthma by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.
The criteria were revised on the registry on Nov 9, 2026. See what changed
severe eosinophilic asthma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients are eligible for inclusion only if all of the following criteria are met:
Exclusion criteria
Patients should not be enrolled if any of the following exclusion criteria are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
non-interventional
Drug: benralizumab
non-interventional
asthma control questionnaire
Change from baseline in the six-item Asthma Control Questionnaire (ACQ-6) score at Week 4 after initiation of benralizumab. The ACQ-6 is a 6-item version of the Asthma Control Questionnaire. The ACQ-6 score is calculated as the mean of the 6 items and ranges from 0 to 6, with higher scores indicating worse asthma control. Change from baseline is calculated as the post-baseline ACQ-6 score at Week 4 minus the baseline ACQ-6 score.
Time frame: Week 4
Rate of exacerbations
• Changes from baseline in annualized rate of exacerbations over 56 weeks after initiation of benralizumab.
Time frame: Week 56
percentage of patients with benralizumab discontinuation
• Percentage of patients with benralizumab discontinuation at Week 24, 40 and 56 after initiation of benralizumab
Time frame: Week 24,40,56
Changes in Lung function
Change from Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (pre-BD FEV1)
Time frame: Weeks 8, 24 and 56 after initiation of benralizumab
Changes in Lung function
Change from Baseline in Forced Vital Capacity (FVC)
Time frame: Weeks 8, 24 and 56 after initiation of benralizumab
Changes in Lung function
Change from Baseline in FEV1/FVC Ratio
Time frame: Weeks 8, 24 and 56 after initiation of benralizumab
Changes in Lung function
Change from Baseline in Peak Expiratory Flow (PEF)
Time frame: Weeks 8, 24 and 56 after initiation of benralizumab
Changes in Lung function
Change from Baseline in Post-bronchodilator FEV1/FVC Ratio
Time frame: Weeks 8, 24 and 56 after initiation of benralizumab
Change from Baseline in Six-item Asthma Control Questionnaire (ACQ-6) Score
The ACQ-6 score ranges from 0 to 6, with higher scores indicating worse asthma control. Change from baseline is calculated as the post-baseline ACQ-6 score minus the baseline ACQ-6 score.
Time frame: Weeks 1, 2, 8, 16, 24, 40 and 56 after initiation of benralizumab
Percentage of Patients by Asthma Control Status Based on ACQ-6 Score
The ACQ-6 score ranges from 0 to 6, with higher scores indicating worse asthma control. Patients are categorized as well controlled (ACQ-6 score ≤0.75), partially controlled (ACQ-6 score \>0.75 and \<1.5), or uncontrolled (ACQ-6 score ≥1.5).
Time frame: Weeks 1, 2, 4, 8, 16, 24, 32, 40, 48 and 56 after initiation of benralizumab
Percentage of Patients With Clinically Meaningful Improvement in ACQ-6 Score
The ACQ-6 score ranges from 0 to 6, with higher scores indicating worse asthma control. Clinically meaningful improvement is defined as at least (≥) a 0.5-unit improvement in ACQ-6 score from baseline.
Time frame: Weeks 1, 2, 4, 8, 16, 24, 40 and 56 after initiation of benralizumab
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jan 2028, 30 months after the start.
Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 30 months is above that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.